Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington [etc.]: American Psychiatric Publishing; 2013.
   Google Scholar
• Polanczyk GV, Salum GA, Sugaya LS, et al. Annual research review: a meta‐analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015;56:345–365.
   PubMed Web of Science ®Google Scholar
• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–948.
   PubMed Web of Science ®Google Scholar
• Simon V, Czobor P, Balint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204–211.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Asherson P, Banaschewski T, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1:15020.
   PubMed Web of Science ®Google Scholar
• World Health Organization. International statistical classification of diseases and related health problems. 11th revision. Geneva: World Health Organization; 2018.
   Google Scholar
• Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020;395:450–462.
   PubMed Web of Science ®Google Scholar
• Ahmed R, Aslani P. Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults. Expert Rev Pharmacoecon Outcomes Res. 2013;13:791.
   PubMed Web of Science ®Google Scholar
• Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Can Med Assoc J. 2001;165:1475–1488.
   PubMed Web of Science ®Google Scholar
• Feldman ME, Charach A, Bélanger SA. ADHD in children and youth: part 2-Treatment. Paediatr Child Health. 2018;23:462–472.
   PubMed Web of Science ®Google Scholar
• Klein RG, Landa B, Mattes JA, et al. Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry. 1988;45:1127.
   PubMed Web of Science ®Google Scholar
• Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018;6:CD007990.
   PubMedGoogle Scholar
• Cunill R, Castells X, Tobias A, et al. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta‐analysis and meta‐regression. Pharmacoepidemiol Drug Saf. 2013;22:961–969.
   PubMed Web of Science ®Google Scholar
• Wu B, Bruns EJ, Tai M, et al. Psychotropic polypharmacy among youths with serious emotional and behavioral disorders receiving coordinated care services. Psychiatric Serv. 2018;69:716–722.
   PubMed Web of Science ®Google Scholar
• Sobel LJ, Bansal R, Maia TV, et al. Basal ganglia surface morphology and the effects of stimulant medications in youth with attention deficit hyperactivity disorder. Am J Psychiatry. 2010;167:977–986.
   PubMed Web of Science ®Google Scholar
• Matosin N, Fernandez-Enright F, Fung SJ, et al. Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation. Acta Neuropathol. 2015;130:119–129.
   PubMed Web of Science ®Google Scholar
• Olsen CM, Childs DS, Stanwood GD, et al. Operant sensation seeking requires metabotropic glutamate receptor 5 (mGluR5). PloS One. 2010;5:e15085.
   PubMed Web of Science ®Google Scholar
• Park G, Jung Y, Park M, et al. Melatonin inhibits attention-deficit/hyperactivity disorder caused by atopic dermatitis-induced psychological stress in an NC/Nga atopic-like mouse model. Sci Rep. 2018;8:1–13.
   PubMed Web of Science ®Google Scholar
• Molina-Carballo A, Naranjo-Gómez A, Uberos J, et al. Methylphenidate effects on blood serotonin and melatonin levels may help to synchronise biological rhythms in children with ADHD. J Psychiatr Res. 2013;47:377–383.
   PubMed Web of Science ®Google Scholar
• Yuen EY, Yan Z. Dopamine D4 receptors regulate AMPA receptor trafficking and glutamatergic transmission in GABAergic interneurons of prefrontal cortex. J Neurosci. 2009;29:550–562.
   PubMed Web of Science ®Google Scholar
• Bossong M, Mehta M, van Berckel B, et al. Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology (Berl). 2015;232:2723–2729.
   PubMed Web of Science ®Google Scholar
• Bossong MG, van Berckel BNM, Boellaard R, et al. Delta 9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology. 2009;34:759–766.
   PubMed Web of Science ®Google Scholar
• Voruganti LNP, Slomka P, Zabel P, et al. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. 2001;107:173–177.
   PubMed Web of Science ®Google Scholar
• Barkus E, Morrison PD, Vuletic D, et al. Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol. 2011;25:1462.
   PubMed Web of Science ®Google Scholar
• Stokes PRA, Mehta MA, Curran HV, et al. Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage. 2009;48:186–190.
   PubMed Web of Science ®Google Scholar
• Potter AS, Newhouse PA, Bucci DJ. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? Behav Brain Res. 2006;175:201–211.
   PubMed Web of Science ®Google Scholar
• Potter AS, Newhouse PA. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacol Biochem Behav. 2008;88:407–417.
   PubMed Web of Science ®Google Scholar
• Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol. 2004;74:363–396.
   PubMed Web of Science ®Google Scholar
• Levin ED, Rezvani AH. Nicotinic-antipsychotic drug interactions and cognitive function. EXS. 2006;98:185.
   PubMedGoogle Scholar
• Lin JS, Sakai K, Vanni-Mercier G, et al. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res. 1990;523:325.
   PubMed Web of Science ®Google Scholar
• Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24:348–358.
   PubMed Web of Science ®Google Scholar
• McBurnett KR A study of PDC-1421 treatment in adult patients with attention-deficit hyperactivity disorder (ADHD). 2016 Mar 1 [last updated 2020 Jan 18; no results posted; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT02699086 ClinicalTrials.gov Identifier: NCT02699086
   Google Scholar
• Zavadenko NN, Suvorinova NY, Vakula IN, et al. Pharmacotherapy of attention deficit hyperactivity disorder in children: the results of a multicenter double-blind placebo-controlled study of hopantenic acid. Zh Nevrol psikhiatr im S.S. Korsakova. 2017;117:39.
   PubMedGoogle Scholar
• Kupriyanova TA, Koren EV, Alabusheva NN. A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam. Zh Nevrol psikhiatr im S.S. Korsakova. 2017;117:75.
   PubMedGoogle Scholar
• Riahi F, Tehrani‐Doost M, Shahrivar Z, et al. Efficacy of reboxetine in adults with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled clinical trial. Hum Psychopharmacol. 2010;25:570–576.
   PubMed Web of Science ®Google Scholar
• Riahi F, Tashakori A, Izadi-Mazidi S, et al. Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit-hyperactivity disorder with comorbid anxiety disorders. Iran J Psychiatry. 2013;8:195–200.
   PubMedGoogle Scholar
• Jin L, Xu W, Krefetz D, et al. Clinical outcomes from an open-label study of edivoxetine use in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23:200.
   PubMed Web of Science ®Google Scholar
• Lin DY, Kratochvil CJ, Xu W, et al. A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24:190.
   PubMed Web of Science ®Google Scholar
• Nery ESM, Bangs M, Liu P, et al. Long-term, open-label, safety study of edivoxetine monotherapy in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27:700.
   PubMed Web of Science ®Google Scholar
• Theravance Biopharma, Inc. A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD). 2011 Oct 20 [last updated 2019 Dic 9; no results posted: certification/extension first submitted 2018 Sept 10; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01458340 ClinicalTrials.gov Identifier: NCT01458340.
   Google Scholar
• Downey L AR08 for Treatment of ADHD in Children. 2013 June 11 [last updated 2015 Dic 9; no results posted: certification/extension first submitted 2015 Jun 5; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01876719 ClinicalTrials.gov Identifier: NCT01876719
   Google Scholar
• Mahmoudi‐Gharaei J, Dodangi N, Tehrani‐Doost M, et al. Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open‐label study. Hum Psychopharmacol. 2011;26:155–160.
   PubMed Web of Science ®Google Scholar
• Bilodeau M, Simon T, Beauchamp MH, et al. Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study. J Atten Disord. 2014;18:169.
   PubMed Web of Science ®Google Scholar
• Jafarinia M, Mohammadi M, Modabbernia A, et al. Bupropion versus methylphenidate in the treatment of children with attention‐deficit/hyperactivity disorder: randomized double‐blind study. Hum Psychopharmacol. 2012;27:411–418.
   PubMed Web of Science ®Google Scholar
• Hamedi M, Mohammdi M, Ghaleiha A, et al. Bupropion in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind study. Acta Med Iran. 2014;52:675–680.
   PubMedGoogle Scholar
• Koblan KS, Hopkins SC, Sarma K, et al. Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology. 2015;40:2745–2752.
   PubMed Web of Science ®Google Scholar
• Findling RL, Adler LA, Spencer TJ, et al. Dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. J Child Adolesc Psychopharmacol. 2019. DOI:10.1089/cap.2018.0083
   Web of Science ®Google Scholar
• Wigal SB, Hopkins SC, Koblan KS, et al. Efficacy and safety of dasotraline in children with ADHD: a laboratory classroom study. J Atten Disord. 2020;24:192.
   PubMed Web of Science ®Google Scholar
• Otsuka Pharmaceutical Development & Commercialization, Inc. A trial evaluating the long-term safety and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder. 2018 June 28 [last updated 2020 Jan 31; no results posted; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT03605849 ClinicalTrials.gov Identifier: NCT03605849.
   Google Scholar
• Otsuka Pharmaceutical Development & Commercialization, Inc. The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder. 2017 Oct 25 [last updated 2019 Oct 9; no results posted: certification/extension first submitted 2019 Oct 1; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT03324581 ClinicalTrials.gov Identifier: NCT03324581
   Google Scholar
• Zarinara A, Mohammadi M, Hazrati N, et al. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Hum Psychopharmacol. 2010;25:530–535.
   PubMed Web of Science ®Google Scholar
• Amiri S, Farhang S, Ghoreishizadeh MA, et al. Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Hum Psychopharmacol. 2012;27:76.
   PubMed Web of Science ®Google Scholar
• Takahama K. Multiple pharmacological actions of centrally acting antitussives — do they target g protein-coupled inwardly rectifying K+ (GIRK) channels? J Pharmacol Sci. 2012;120:146–151.
   PubMed Web of Science ®Google Scholar
• Soeda F, Fujieda Y, Kinoshita M, et al. Centrally acting non-narcotic antitussives prevent hyperactivity in mice: involvement of GIRK channels. Pharmacol Biochem Behav. 2016;144:26–32.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Hashimoto K, Tachibana M, et al. Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study. Neuropsychiatr Dis Treat. 2014;10:147–151.
   PubMed Web of Science ®Google Scholar
• Tomoda A, Takiguchi S, Fujisawa TX, et al. Effectiveness of oral tipepidine administration for children with attention deficit/hyperactivity disorder: a 4-week, open-label clinical study: effectiveness of tipepidine in ADHD. Psychiatry Clin Neurosci. 2015;69:658–659.
   PubMed Web of Science ®Google Scholar
• Dehbozorghi S, Bagheri S, Moradi K, et al. Efficacy and safety of tipepidine as adjunctive therapy in children with attention‐deficit/hyperactivity disorder: randomized, double‐blind, placebo‐controlled clinical trial. Psychiatry Clin Neurosci. 2019;73:690–696.
   PubMed Web of Science ®Google Scholar
• Biederman J, Lindsten A, Sluth LB, et al. Vortioxetine for attention deficit hyperactivity disorder in adults: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol. 2019;33:511.
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Kazemi M, Zia E, et al. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double‐blind trial. Hum Psychopharmacol. 2010;25:560–565.
   PubMed Web of Science ®Google Scholar
• Surman CBH, Hammerness PG, Petty C, et al. A pilot open label prospective study of memantine monotherapy in adults with ADHD. World J Biol Psychiatry. 2013;14:291.
   PubMed Web of Science ®Google Scholar
• Mohammadi MR, Mohammadzadeh S, Akhondzadeh S. Memantine versus methylphenidate in children and adolescents with attention deficit hyperactivity disorder: a double-blind, randomized clinical trial. Iran J Psychiatry. 2015;10:106–114.
   PubMedGoogle Scholar
• Mohammadzadeh S, Ahangari TK, Yousefi F. The effect of memantine in adult patients with attention deficit hyperactivity disorder. Hum Psychopharmacol. 2019;34:e2687-n/a.
   PubMed Web of Science ®Google Scholar
• Biederman J, Fried R, Tarko L, et al. Memantine in the treatment of executive function deficits in adults with ADHD. J Atten Disord. 2017;21(4):343.
   PubMed Web of Science ®Google Scholar
• Elia J, Ungal G, Kao C, et al. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nat Commun. 2018;9:4–9.
   PubMed Web of Science ®Google Scholar
• Adler LA, Kroon RA, Stein M, et al. A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2012;72:971–977.
   PubMed Web of Science ®Google Scholar
• Tzang R-F Placebo-controlled trial with GlyTI-M among children with attention deficit hyperactivity disorder (ADHD). 2012 Nov 6 [last updated 2013 Jul 16; no results posted; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01725737 ClinicalTrials.gov Identifier: NCT01725737
   Google Scholar
• Mohammadi MR, Mostafavi SA, Keshavarz SA, et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iran J Psychiatry. 2012;7:87–92.
   PubMedGoogle Scholar
• Niederhofer H. Agomelatine treatment with adolescents with ADHD. J Atten Disord. 2012;16:530.
   PubMed Web of Science ®Google Scholar
• Salardini E, Zeinoddini A, Kohi A, et al. Agomelatine as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double-blind, randomized clinical trial. J Child Adolesc Psychopharmacol. 2016;26:513.
   PubMed Web of Science ®Google Scholar
• Stocks JD, Taneja BK, Baroldi P, et al. A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. J Child Adolesc Psychopharmacol. 2012;22:102.
   PubMed Web of Science ®Google Scholar
• Rivkin A, Alexander RC, Knighton J, et al. A randomized, double-blind, crossover comparison of MK-0929 and placebo in the treatment of adults with ADHD. J Atten Disord. 2012;16:664.
   PubMed Web of Science ®Google Scholar
• Cooper RE, Williams E, Seegobin S, et al. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27:795–808.
   PubMed Web of Science ®Google Scholar
• Herring WJ, Wilens TE, Adler LA, et al. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2012;73:e891–e898.
   PubMedGoogle Scholar
• Weisler RH, Pandina GJ, Daly EJ, et al. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012;26:421–434.
   PubMed Web of Science ®Google Scholar
• Moorthy G, Sallee F, Gabbita P, et al. Safety, tolerability and pharmacokinetics of 2-pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD: pharmacokinetics of 2-pyridylacetic acid, a metabolite of betahistine. Biopharm Drug Dispos. 2015;36:429–439.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry. 2006;59:1065–1070.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Gault LM, Childress A, et al. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry. 2011;2010;50:73.
   PubMed Web of Science ®Google Scholar
• Apostol G, Abi-Saab W, Kratochvil CJ, et al. Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl). 2012;219:715–725.
   PubMed Web of Science ®Google Scholar
• Bain EE, Apostol G, Sangal RB, et al. A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2012;73:783–789.
   PubMed Web of Science ®Google Scholar
• Ji J, Schrimpf MR, Sippy KB, et al. Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists. J Med Chem. 2007;50:5493.
   PubMed Web of Science ®Google Scholar
• Bain EE, Robieson W, Pritchett Y, et al. A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD. Neuropsychopharmacology. 2013;2012(38):405–413.
   Google Scholar
• Jucaite A, Öhd J, Potter AS, et al. A randomized, double-blind, placebo-controlled crossover study of α4β 2 nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2014;231:1251.
   PubMed Web of Science ®Google Scholar
• Potter AS, Dunbar G, Mazzulla E, et al. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. Biol Psychiatry. 2014;75:207–214.
   PubMed Web of Science ®Google Scholar
• Wilens T Safety & efficacy of TC-5619 in adults with inattentive-predominant attention deficit/hyperactivity disorder (ADHD). 2011 Nov 14 [last updated 2013 Apr 30; no results posted: certification/extension first submitted 2013 Apr 22; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01472991 ClinicalTrials.gov Identifier: NCT01472991
   Google Scholar
• Adler L CX717 in the Treatment of Adult ADHD. 2017 Dec 7 [last updated 2017 Dec 15; no results posted; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT03375021 ClinicalTrials.gov Identifier: NCT03375021
   Google Scholar
• Plessow F. Oxytocin and Cognitive Control in Adult ADHD. 2017 Apr 26 [ last updated 2020 Feb 19; no results posted; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT03136263 ClinicalTrials.gov Identifier: NCT03136263
   Google Scholar
• Hwang S Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders. 2016 June 27 [last updated 2019 Mar 5; no results posted; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT02824627 ClinicalTrials.gov Identifier: NCT02824627.6
   Google Scholar
• NeuroDerm Ltd. A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD). 2010 Aug 1 [ last updated 2019 Dec 5; no results posted; cited 2020 Apr 21]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01174355 ClinicalTrials.gov Identifier: NCT01174355
   Google Scholar
• Spencer TJ, Brown A, Seidman LJ, et al. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. J Clin Psychiatry. 2013;74:902–917.
   PubMed Web of Science ®Google Scholar
• Posner J, Nagel BJ, Maia TV, et al. Abnormal amygdalar activation and connectivity in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:828.
   PubMed Web of Science ®Google Scholar
• Mauri M, Nobile M, Bellina M, et al. Light up ADHD: I. cortical hemodynamic responses measured by functional near infrared spectroscopy (fNIRS). J Affect Disord. 2018;234:358–364.
   PubMedGoogle Scholar
• Grazioli S, Mauri M, Crippa A, et al. Light up ADHD: II. Neuropharmacological effects measured by near infrared spectroscopy: is there a biomarker? J Affect Disord. 2019;244:100–106.
   PubMed Web of Science ®Google Scholar
• Pozzi M, Carnovale C, Peeters GGAM, et al. Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: a meta-analysis. J Affect Disord. 2018;238:161–178.
   PubMed Web of Science ®Google Scholar
• Pozzi M, Carnovale C, Mazhar F, et al. Adverse drug reactions related to mood and emotion in pediatric patients treated for attention deficit/hyperactivity disorder: a comparative analysis of the us food and drug administration adverse event reporting system database. J Clin Psychopharmacol. 2019;39(4):386–392.
   PubMed Web of Science ®Google Scholar